Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Hord

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2006
Do parents have the right to refuse standard treatment for their child with favorable-prognosis cancer? Ethical and legal concernsJeffrey D Hord, Waqas Rehman, Patricia Hannon, et al.
The Journal of Supportive Oncology|December 17, 2005
Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapyPamela S Hinds, Marilyn Hockenberry, James Feusner, et al.
Pediatric Blood & Cancer|May 21, 2016
Central Line Associated Blood Stream Infections in Pediatric Hematology/Oncology Patients With Different Types of Central LinesJeffrey D Hord, John Lawlor, Eric Werner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapyBassem I Razzouk, Jeffrey D Hord, Marilyn Hockenberry, et al.
Journal of Pediatric Hematology/Oncology|May 1, 1995
Long-term granulocyte-macrophage colony-stimulating factor and immunosuppression in the treatment of acquired severe aplastic anemiaJ D Hord, J C Gay, J A Whitlock, et al.
Pediatric Blood & Cancer|October 15, 2009
High-dose cyclophosphamide treatment for refractory severe aplastic anemia in childrenAnthony N Audino, Julie Blatt, Benjamin Carcamo, et al.
Biological Trace Element Research|November 21, 2013
Applications of neutron activation analysis to the study of age-related neurological diseasesW D Ehmann, W R Markesbery, E J Kasarskis, et al.
Infection Control and Hospital Epidemiology|April 13, 2017
A Prospective, Holistic, Multicenter Approach to Tracking and Understanding Bloodstream Infections in Pediatric Hematology-Oncology PatientsAditya H Gaur, David G Bundy, Eric J Werner, et al.
Pediatric Blood & Cancer|May 10, 2020
Mucosal barrier injury-associated bloodstream infections in pediatric oncology patientsHana Hakim, Amy L Billett, Jiahui Xu, et al.
Leukemia|February 1, 1997
High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemiaJ A Whitlock, R J Wells, J D Hord, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2006
Do parents have the right to refuse standard treatment for their child with favorable-prognosis cancer? Ethical and legal concernsJeffrey D Hord, Waqas Rehman, Patricia Hannon, et al.
The Journal of Supportive Oncology|December 17, 2005
Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapyPamela S Hinds, Marilyn Hockenberry, James Feusner, et al.
Pediatric Blood & Cancer|May 21, 2016
Central Line Associated Blood Stream Infections in Pediatric Hematology/Oncology Patients With Different Types of Central LinesJeffrey D Hord, John Lawlor, Eric Werner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapyBassem I Razzouk, Jeffrey D Hord, Marilyn Hockenberry, et al.
Journal of Pediatric Hematology/Oncology|May 1, 1995
Long-term granulocyte-macrophage colony-stimulating factor and immunosuppression in the treatment of acquired severe aplastic anemiaJ D Hord, J C Gay, J A Whitlock, et al.
Pediatric Blood & Cancer|October 15, 2009
High-dose cyclophosphamide treatment for refractory severe aplastic anemia in childrenAnthony N Audino, Julie Blatt, Benjamin Carcamo, et al.
Biological Trace Element Research|November 21, 2013
Applications of neutron activation analysis to the study of age-related neurological diseasesW D Ehmann, W R Markesbery, E J Kasarskis, et al.
Infection Control and Hospital Epidemiology|April 13, 2017
A Prospective, Holistic, Multicenter Approach to Tracking and Understanding Bloodstream Infections in Pediatric Hematology-Oncology PatientsAditya H Gaur, David G Bundy, Eric J Werner, et al.
Pediatric Blood & Cancer|May 10, 2020
Mucosal barrier injury-associated bloodstream infections in pediatric oncology patientsHana Hakim, Amy L Billett, Jiahui Xu, et al.
Leukemia|February 1, 1997
High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemiaJ A Whitlock, R J Wells, J D Hord, et al.
Pageof 4